Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 71335-9750

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 71335-9750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing plasma concentration over time (hours) of extended-release guanfacine 1 mg QD and immediate-release guanfacine 1 mg QD. The y-axis shows guanfacine plasma concentration (ng/mL), and the x-axis shows time in hours up to 24 hours, illustrating differing absorption profiles between the two formulations.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A pharmacokinetic chart showing fold changes and 90% confidence intervals in Cmax and AUC values of guanfacine extended-release due to co-administration with various CYP3A4/5 inhibitors, inducers, and other drugs. The horizontal axis represents fold change relative to reference, with plotted data points and error bars for ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart showing pharmacokinetic fold changes with 90% confidence intervals for the drugs Oral Methylphenidate and Lisdexamfetamine Dimesylate. The variables include Cmax and AUC, with a horizontal axis representing change relative to reference values from 0.0 to 2.0.*
FDA Label Image

Figure4.jpg (Figure4)

Figure4.jpg (Figure4)
A line chart depicting treatment failure percentage over time in days. The x-axis represents time to treatment failure from 0 to 203 days, while the y-axis shows treatment failure percentage from 0% to 100%. Two lines are shown: a solid line for placebo and a dashed line for SPD503, illustrating lower treatment failure rates with SPD503 over the study period.*
FDA Label Image

Label (Lbl713359750)

Label (Lbl713359750)
Label for Guanfacine extended-release tablets USP 2 mg by Bryant Ranch Prepack. The label states NDC 71335-9750-1 and indicates a package of 30 tablets. It includes storage instructions, warnings not to crush or chew tablets, and manufacturer Apotex Inc. Additional barcodes and repackaging details are also visible.*
FDA Label Image

Spd503-chemical-stucture (Spd503 Chemical Stucture)

Spd503-chemical-stucture (Spd503 Chemical Stucture)
Chemical structure of guanfacine hydrochloride, showing its molecular arrangement including chlorine atoms and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.